Zusammenfassung
Therapeutisch werden peripher und zentral wirkende Muskelrelaxantien unterschieden. Während peripher wirkende Muskelrelaxantien klinisch vor allem zur Muskelrelaxation bei Narkose eingesetzt werden, kommen zentral wirkende Muskelrelaxantien bei der Behandlung krankhafter Tonuserhöhungen der Skelettmuskulatur zur Anwendung. Periphere Muskelrelaxantien lassen sich nach ihrem Wirkmechanismus in depolarisierende (z. B. Suxamethoniumchlorid) und nichtdepolarisierende Muskelrelaxantien (z. B. Tubocurarin, Atracurium, Rocuronium etc.) einteilen. Sie hemmen die neuromuskuläre Übertragung an der motorischen Endplatte der Skelettmuskulatur und führen so zu einer Erschlaffung der quergestreiften Muskulatur. Hinzu kommen Substanzen, die die periphere Acetylcholinfreisetzung an den präsynaptischen Nervenendigungen der motorischen Endplatte verhindern (Botulinumtoxin) oder postsynaptisch die elektromechanische Kopplung hemmen (Dantrolen).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bröse HD, Repges R, Dethlefsen U (1996): Therapie schmerzhafter Kontraktionen der Skelettmuskulatur — Doppelblinder Parallelgruppenvergleich zwischen den zentral wirksamen Myotonolytika Methocarbamol und Tetrazepam. Münch Med Wschr 138:726–731.
Chou R, Peterson K, Helfand M (2004): Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 28: 140–175.
Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2004): Botulinum toxin type A therapy for blepharospasm. In: The Cochrane Database of Systematic Reviews: Reviews 2004, Issue 2, John Wiley & Sons, Ltd Chichester, UK.
Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005a): Botulinum toxin type A therapy for cervical dystonia. In: The Cochrane Database of Systematic Reviews: Reviews 2005, Issue 1, John Wiley & Sons, Ltd Chichester, UK.
Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C. Botulinum toxin type A therapy for hemifacial spasm (2005b): The Cochrane Database of Systematic Reviews: Reviews 2005, Issue 1, John Wiley & Sons, Ltd Chichester, UK.
Deutsche Gesellschaft für Neurologie (2005): Leitlinie Spastik. http://www.dgn.org/130.0.html. Letzter Zugriff 25. April 2007
Keane RE, Simiand J, Morre M, Biziere K (1988a): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exp Ther 245: 692–698.
Keane RE, Bachy A, Morre M, Biziere K (1988b): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites. J Pharmacol Exp Ther 245: 699–705.
Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F (2001): Botulinumtoxin — Neue Therapieoption für Kinder mit Zerebralparese. Dtsch Ärzteblatt 98: A3375–A3379.
Pratzel HG, Alken RG, Ramm S (1996): Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain 67: 417–425.
Preston KL, Guarino JJ, Kirk WT, Griffiths RR (1989): Evaluation of the abuse potential of methocarbamol. J Pharmacol Exp Ther 248: 1146–1157.
Preston KL, Wolf B, Guarino JJ, Griffiths RR (1992): Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J Pharmacol Exp Ther 262: 707–720.
Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W (2008): Tolperisone: A typical representative of a class of centrally acting muscle Relexnants with less sedative side effects. CNS Neurol Therap 14: 107–119.
Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001332. DOI: 10.1002/14651858.CD001332.
Simiand J, Keane PE, Biziere K, Soubrie P (1989): Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn Ther 297: 272–285.
Stamenova P, Koytchev R, Kuhn K, Hansen C, Horvath F, Ramm S, Pongratz D (2005) A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol 12: 453–461.
Tisdale SA, Ervin DK (1975): A controlled study of methocarbamol (Robaxin®) in acute painful musculoskeletal conditions. Curr Ther Res 17: 525–530.
Valtonen EJ (1975): A double-blind trial of methocarbamol versus placebo in painful muscle spasm. Curr Med Res Op 3: 382–385.
Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschier E, Kropfgans M et al (1993): Thermodynamics of antagonist binding to rat muscarinic M2 receptors: antimuscarinics of the pridinol, sila-pridinol, diphenidol and sila-diphenidol type. Br J Pharmacol 109: 360–370.
Wasiak J, Hoare B, Wallen M (2004) Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database of Systematic Reviews 2004, Issue 4. Art.No.: CD003469. DOI: 10.1002/14651858.CD003469.pub3.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Günther, J. (2009). Muskelrelaxantien. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2009. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01080-4_35
Download citation
DOI: https://doi.org/10.1007/978-3-642-01080-4_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01079-8
Online ISBN: 978-3-642-01080-4
eBook Packages: Medicine (German Language)